1. Home
  2. LFMD vs SLGL Comparison

LFMD vs SLGL Comparison

Compare LFMD & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LifeMD Inc.

LFMD

LifeMD Inc.

HOLD

Current Price

$3.14

Market Cap

218.1M

Sector

Health Care

ML Signal

HOLD

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

N/A

Current Price

$77.20

Market Cap

254.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LFMD
SLGL
Founded
1994
1997
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.1M
254.1M
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
LFMD
SLGL
Price
$3.14
$77.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
$9.14
$110.00
AVG Volume (30 Days)
1.0M
42.4K
Earning Date
05-06-2026
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
141.67
N/A
EPS
N/A
N/A
Revenue
$12,468,578.00
N/A
Revenue This Year
$17.52
N/A
Revenue Next Year
$18.73
$223.84
P/E Ratio
N/A
N/A
Revenue Growth
49.79
N/A
52 Week Low
$2.60
$20.10
52 Week High
$7.32
$97.97

Technical Indicators

Market Signals
Indicator
LFMD
SLGL
Relative Strength Index (RSI) 35.75 45.94
Support Level $3.00 $67.89
Resistance Level $3.41 $81.18
Average True Range (ATR) 0.25 6.36
MACD 0.00 -0.89
Stochastic Oscillator 14.20 33.93

Price Performance

Historical Comparison
LFMD
SLGL

About LFMD LifeMD Inc.

LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.

Share on Social Networks: